Can larotrectinib treat lung cancer?

Larotrectinib is a targeted drug targeting NTRK (neurotrophic tyrosine receptor kinase) gene fusion and can be used to treat a variety of solid tumors, including lung cancer. A key condition for its treatment is that the patient's tumor carries an NTRK gene fusion, a rare but important cancer driver. Regardless of the tissue source of the tumor, if the NTRK gene fusion is confirmed, the patient can be treated with larotrectinib.

Larotrectinib has been proven effective in patients with NTRK gene fusion-positive non-small cell lung cancer (NSCLC). In relevant clinical trials, larotrectinib showed a high objective response rate (ORR) in such patients. Studies show that about 70%-80% of patients have significant responses to the drug, including partial and complete remissions. For patients with advanced lung cancer who have developed distant metastasis, larotrectinib can also effectively control the disease and prolong survival.

Larotrectinib blocks the growth and spread of cancer cells by inhibiting TRK protein signaling. NTRK Gene fusion leads to the continuous activation of TRK protein, driving abnormal proliferation of cancer cells. Therefore, larotrectinib's targeting of this specific molecular mechanism makes it a representative drug for precision therapy.

Although larotrectinib is effective in patients with lung cancer carrying NTRK gene fusions, the incidence of NTRK gene fusions in lung cancer is low, accounting for only about 1%-2% of all non-small cell lung cancer cases. Therefore, molecular testing is required before using larotrectinib to confirm the presence of gene fusion. In addition, this drug is not currently included in domestic medical insurance, and the price is relatively high, which may impose a greater financial burden on patients.

Larotrectinib is indicated for the treatment of NTRK gene fusion-positive lung cancer patients, regardless of cancer stage and specific type. Its efficacy is remarkable and provides a new treatment option for patients with advanced or drug-resistant lung cancer.

xa0

Reference materials:

1.FDADrug Description:https://www.fda.gov

2.NCCNGuidelines:https://www.nccn.org

3.PubMedAcademic literature:https://pubmed.ncbi.nlm.nih.gov